Physician profile
V Hema Kumar
NPI 1376517458
$3,853.91
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,019 · 2020: $471 · 2021: $1,145 · 2022: $122 · 2024: $97.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $97.58.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $97.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $747.36 | 2019-2021 | |
| Allergan, INC. | $340.19 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $328.69 | 2019-2021 | |
| Sanofi US Services INC. | $325.00 | 2021 | |
| Sunovion Pharmaceuticals INC. | $237.32 | 2019-2020 | |
| Novo Nordisk INC | $232.24 | 2019-2021 | |
| Pfizer INC. | $208.87 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $180.03 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $161.45 | 2019 | |
| Genentech USA, INC. | $159.74 | 2019 | |
| Novartis Pharmaceuticals Corporation | $137.61 | 2019 | |
| Sun Pharmaceutical Industries INC. | $125.00 | 2021 | |
| Urovant Sciences INC | $125.00 | 2021 | |
| Amgen INC. | $123.41 | 2020 | |
| Edwards Lifesciences Corporation | $122.48 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $120.02 | 2019 | |
| Valeritas, INC. | $81.92 | 2019 | |
| Medtronic, INC. | $80.09 | 2024 | Cobalt Dr Mri Surescan |
| Medline Industries LP | $17.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw V Hema Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.